Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Wasif Saif

Showing results (381-390 of 473) with videos related to

Pageof 48
Sort By:
JOP : Journal of the Pancreas|March 13, 2012
Pancreatic neuroendocrine tumors: entering a new eraPaul E Oberstein, Helen Remotti, Muhammad Wasif Saif, et al.
Expert Opinion on Drug Safety|December 25, 2018
The safety of lanreotide for neuroendocrine tumorAmandeep Godara, Nauman S Siddiqui, Margaret M Byrne, et al.
Anti-Cancer Drugs|November 1, 2006
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to responseVladimir Gotlib, Samer Khaled, Igor Lapko, et al.
Therapeutics and Clinical Risk Management|March 25, 2008
Hypokalemia secondary to capecitabine: a hidden toxicity?Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, et al.
Cancer Medicine Journal|July 1, 2020
Consequences of the COVID-19 Pandemic on Cancer Clinical TrialsSally Flores, Nita Kurian, Anu Yohannan, et al.
JOP : Journal of the Pancreas|July 17, 2012
New tools and novel approaches in treating locally advanced pancreatic adenocarcinomaWesam B Ahmed, John Ng, David E Wazer, et al.
Clinical Colorectal Cancer|August 24, 2011
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new eraRoland El-Ghazal, Nikolai Podoltsev, Peter Marks, et al.
Clinical Colorectal Cancer|October 14, 2009
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?Edward James, Nikolai Podoltsev, Elahe Salehi, et al.
JOP : Journal of the Pancreas|March 11, 2008
Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?Kyle T Elligers, Marianne Davies, Desiree Sanchis, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2006
Dihydropyrimidine dehydrogenase deficiency in an Indian populationMuhammad Wasif Saif, Lori Mattison, Tom Carollo, et al.
Pageof 48

Showing results (381-390 of 473) with videos related to

Sort By:
Pageof 48
JOP : Journal of the Pancreas|March 13, 2012
Pancreatic neuroendocrine tumors: entering a new eraPaul E Oberstein, Helen Remotti, Muhammad Wasif Saif, et al.
Expert Opinion on Drug Safety|December 25, 2018
The safety of lanreotide for neuroendocrine tumorAmandeep Godara, Nauman S Siddiqui, Margaret M Byrne, et al.
Anti-Cancer Drugs|November 1, 2006
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to responseVladimir Gotlib, Samer Khaled, Igor Lapko, et al.
Therapeutics and Clinical Risk Management|March 25, 2008
Hypokalemia secondary to capecitabine: a hidden toxicity?Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, et al.
Cancer Medicine Journal|July 1, 2020
Consequences of the COVID-19 Pandemic on Cancer Clinical TrialsSally Flores, Nita Kurian, Anu Yohannan, et al.
JOP : Journal of the Pancreas|July 17, 2012
New tools and novel approaches in treating locally advanced pancreatic adenocarcinomaWesam B Ahmed, John Ng, David E Wazer, et al.
Clinical Colorectal Cancer|August 24, 2011
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new eraRoland El-Ghazal, Nikolai Podoltsev, Peter Marks, et al.
Clinical Colorectal Cancer|October 14, 2009
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?Edward James, Nikolai Podoltsev, Elahe Salehi, et al.
JOP : Journal of the Pancreas|March 11, 2008
Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?Kyle T Elligers, Marianne Davies, Desiree Sanchis, et al.
Cancer Chemotherapy and Pharmacology|January 20, 2006
Dihydropyrimidine dehydrogenase deficiency in an Indian populationMuhammad Wasif Saif, Lori Mattison, Tom Carollo, et al.
Pageof 48